WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > France Biotech
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Medical
Genelux Corporation | September 29, 2021
Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...
AI
Benchling | January 27, 2023
On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer com...
Cell and Gene Therapy
Elastrin Therapeutics Inc. | January 17, 2022
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA...
Investors Chronicle | April 30, 2020
Healthcare companies around the world are scrambling to produce drugs and vaccines to treat and immunise people against Covid-19. However, the managers of International Biotechnology Trust (IBT) are not necessarily investing in these companies as their share prices are volatile, shooting up on reports of possible treatments in development.For example, Carl Harald Janson, lead manager of International Biotechnology Trust, recently reduced the trust’s holding in Gilead Sciences (US:GIL...
Video
Cell and Gene Therapy, Industrial Impact
Whitepaper
Research, Medical
Medical, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE